Acrux
Melbourne
About Acrux
Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin. Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a contraceptive. 20 human clinical trials have been completed with 8 different drugs and the lead product, Evamist(TM), is nearing the end of a phase 3 trial in the USA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2020)
- Ticker: asx:ACR
- Website: acrux.com.au
- Phone: +61 3 8379 0100
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/acrux-182510 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.